ArticleCureus2023

Apremilast Add-On Benefits Over Conventional Drugs (ABCD) in Unstable Non-segmental Vitiligo: A 12-Week Single-Center Randomized Controlled Trial.

Sakshi Sharma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.